Physician profile
Nan Jiang
NPI 1407883259
$8,721.47
in general payments reported to CMS, 2019-2025
45 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $1,359 · 2021: $1,612 · 2022: $1,412 · 2023: $957 · 2024: $1,243 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,785.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,733.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $780.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $550.64 | 2021-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $459.04 | 2020-2025 | Vemlidy |
| Amarin Pharma, INC. | $446.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $375.18 | 2019-2023 | Steglatro |
| Amgen INC. | $319.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.53 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $249.21 | 2019-2024 | |
| Glaxosmithkline, LLC. | $246.15 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $223.33 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.77 | 2021-2024 | |
| Dexcom, INC. | $146.32 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $135.04 | 2023-2025 | Cologuard Collection Kit |
Show all 39 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.